As of November 6, 2026, Sarepta Therapeutics, Inc. is a publicly traded company (Nasdaq: SRPT); its largest reported holder is BlackRock, with 15.8% on Schedule 13G/A of July 30, 2026, then State Street (8.4%). The largest insider holding is Richard Barry, a director, with 3,233,542 shares (3.0% of shares outstanding), per Form 4 of June 5, 2026 (Schedule 13G/A, July 30, 2026).
Is this your company?
About to sign with, pay or invest in Sarepta Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Sarepta Therapeutics, Inc. a real, registered company?
- Sarepta Therapeutics, Inc. files with the SEC under CIK 873303 (its SEC filings).
- Its shares are listed under the ticker SRPT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Sarepta Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Michael Severino, Chief Executive Officer (Form 8-K filed 2026-07-27). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names AQR (filed 2026-08-13).
Who are Sarepta Therapeutics, Inc.'s owners and officers?
Sarepta Therapeutics, Inc.: incorporated in Delaware; business address in Cambridge, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-13).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Aqr Capital Management, LLC | 5.05% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 8.4% |
| Schedule 13G/A, 2026-07-31 | Vanguard Portfolio Management | 8.05% |
| Schedule 13G/A, 2026-07-30 | Blackrock, Inc. | 15.8% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.11% |
| Schedule 13G, 2026-04-29 | Vanguard Portfolio Management | 6.43% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-02-13 | Aqr Capital Management, LLC | 7.73% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 12.6% |
| Schedule 13G/A, 2025-11-14 | D. E. Shaw & Co., L.P. | 1.9% |
| Schedule 13G, 2025-11-10 | State Street Corporation | 5.4% |
| Schedule 13G/A, 2025-09-08 | The Vanguard Group | 10.89% |
Questions about who owns Sarepta Therapeutics, Inc.
Who owns Sarepta Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Sarepta Therapeutics, Inc.: Blackrock, Inc. (15.8%, Schedule 13G/A, filed 2026-07-30), State Street Corporation (8.4%, Schedule 13G, filed 2026-08-07), Vanguard Portfolio Management (8.05%, Schedule 13G/A, filed 2026-07-31), Vanguard Capital Management (5.11%, Schedule 13G, filed 2026-04-30) and Aqr Capital Management, LLC (5.05%, Schedule 13G/A, filed 2026-08-13).
Who are the largest shareholders of Sarepta Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Sarepta Therapeutics, Inc. on this page are Blackrock, Inc. (15.8%), State Street Corporation (8.4%) and Vanguard Portfolio Management (8.05%).
When did Blackrock, Inc. buy into Sarepta Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-01-21, reporting 12.6%; its latest, Schedule 13G/A filed 2026-07-30, reports 15.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Sarepta Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Sarepta Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sarepta Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-27 | Michael Severino | Chief Executive Officer | appointed | 2026-07-28 |
| Form 8-K, 2026-07-27 | Michael Severino | Director | appointed | |
| Form 8-K, 2026-07-27 | Douglas Ingram | Chief Executive Officer | departed |
Which insiders own Sarepta Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 3,233,542 shares (3.0% of shares outstanding), 2,983,542 held directly and 250,000 indirectly (Form 4, 2026-06-05).
- , the chief executive and a director: 929,391 shares (0.87% of shares outstanding) (Form 4, 2025-12-09).
- , the chief executive and a director: 756,104 shares (0.71% of shares outstanding) (Form 4, 2026-07-29).
- , a director: 504,027 shares (0.47% of shares outstanding), 27,535 held directly and 476,492 indirectly (Form 4, 2026-06-05).
- , a director: 224,357 shares (0.21% of shares outstanding), 214,357 held directly and 10,000 indirectly (Form 4, 2026-06-05).
Shares outstanding: 107,235,848 as of 2026-11-02, from the company's latest SEC cover page.
How much has Sarepta Therapeutics, Inc. raised?
No fundraising or offering filing from Sarepta Therapeutics, Inc. is on file with us.
Keep reading
More on Sarepta Therapeutics, Inc. and the records around it.
Sarepta Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Jul 2026
Companies that share a holder
- D. E. Shaw & Co., L.P. also filed stake reports on 28 other companies: Gossamer Bio, Inc. (Oct 2026), Sweetgreen, Inc. (Oct 2026), Venture Global, Inc. (Sep 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/sarepta-therapeutics